Navigation Links
Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
Date:9/24/2007

ogy to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical ind
'/>"/>

SOURCE Modigene Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... N.H. , March 2, 2015 /PRNewswire/ ... provider of professional-grade vitamins, supplements, prescription products ... announced a strategic partnership with Anabolic Laboratories, ... for healthcare professionals. This new partnership will ... into new licensed healthcare practitioner segments and ...
(Date:3/2/2015)... March 2, 2015  BC Technical, the nation,s ... acquired Eclipse Systems, a Nuclear Imaging service company ... part of their ongoing vision to provide the ... rate, BC Technical continues to expand their reach ... to add valuable resources and knowledge in addition ...
(Date:3/2/2015)... Corporation (NYSE: XON ), a leader ... and full year results for 2014.  ... Acquired ActoGeniX, a European clinical stage biopharmaceutical company ... other innovative products.  Its proprietary TopAct™ platform enables ... lactis ) to generate biologically-contained ActoBiotics™ for in ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3BC Technical Acquires Eclipse Systems 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24
... Calif., Nov. 19 WaferGen Biosystems, Inc. (OTC ... genetic analysis systems, today announced a new, innovative ... using the SmartChip(TM) Real-Time PCR System. By ... WaferGen will offer universities, pharmaceutical and diagnostic companies ...
... , SAN DIEGO, Nov. 19 ... first point-of-care method for measuring platelet reactivity, announces that ... methods evaluated in the POPular study, which was presented ... American Heart Association,s annual Scientific Sessions. The VerifyNow P2Y12 ...
Cached Medicine Technology:WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 2WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 3WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System 4VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests 2
(Date:3/3/2015)... 2015 HealthCarePoint (HCP) , ... announced today that it has completed development of ... Interchange Standards Consortium (CDISC). HCP will continue to ... knowledge-based training and certifications globally. HCP’s in-kind services ... support as well as development of dynamic identification ...
(Date:3/3/2015)... 03, 2015 Aureus Medical Group (web: ... jobs, has announced that it will participate as an ... Tuesday, March 17, 2015 in St. Louis, MO. , ... meet job-seeking residents and fellows in a comfortable, relaxed ... will be available to speak with attendees about ...
(Date:3/3/2015)... Join colleagues from across the continent at ... The Learning Summit is a working retreat for community ... explore strategies for focusing entire colleges on improving and ... at the Community College Research Center, Teachers College, Columbia ... Monday through Wednesday, the program will devote a half-day ...
(Date:3/2/2015)... Getting customers to discover a whole new world in ... the 31st annual Frozen Food Month kicks off. The ... Foods Association (NFRA) to stimulate the awareness and options ... frozen selections and is thrilled to be part of ... crafted with simple ingredients, no preservatives or artificial ingredients. ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor ... Doctors on Liens to bring his medical ... for personal injury victims to have access to multiple ... lien basis. However, San Diego Chiropractic Group ... M.D., pain management physician, massage, and acupuncture to help ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:Register Today for the League for Innovation in the Community College’s Learning Summit 2015 2Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2
... the University of Pennsylvania School of Medicine in,Philadelphia, USA, has ... day have,impaired mental ability much similar to those who go ... was published in the March issue of the,journal Sleep involved ... hours a night for two weeks, the second group slept ...
... of Neurology, London has shown that,there are several preliminaries ... with migraine attacks that identification of these symptoms,would give ... it better.// ,The group of 97 participants were ... attack on a daily basis for three months. The ...
... rules that would help improve patient safety by reducing medication ... as many as 7,000 deaths. These errors have been attributed ... doctors on prescriptions, or too many new drugs for doctors ... 1999 study reported// between 45,000 and 98,000 death due to ...
... Stargardt's macular degeneration, also called juvenile macular degeneration, is ... people. This condition results from a defect in the ... protein that removes all-trans-retinaldehyde, a vision byproduct, from retinal ... retinal-pigmented epithelium (RPE), a layer of cells near the ...
... Health and Nutrition Examination Survey has now uncovered a ... is a form of gum disease that causes infection ... teeth. The participants of the study where divided into ... from the teeth, an indicator of the presence of ...
... heart beat, during recovery after exercise has been found ... increased risk of death and one that occurs during ... with no history of heart failure, valve disease or ... see if frequent ventricular ectopy occurred and when it ...
Cached Medicine News:
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... Coagulation tubes contain a ... is available with a citrate ... or 0.129 mol/l (3.8%). The ... citrate solution to 9 parts ...
Inquire...
Inquire...
Medicine Products: